Rocket Pharmaceuticals (RCKT) and Its Peers Head to Head Comparison

Rocket Pharmaceuticals (NASDAQ: RCKT) is one of 298 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Rocket Pharmaceuticals to similar companies based on the strength of its profitability, dividends, valuation, analyst recommendations, institutional ownership, earnings and risk.

Analyst Ratings

This is a breakdown of current recommendations for Rocket Pharmaceuticals and its rivals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rocket Pharmaceuticals 0 2 2 0 2.50
Rocket Pharmaceuticals Competitors 1350 3805 12543 279 2.65

Rocket Pharmaceuticals presently has a consensus price target of $10.67, indicating a potential downside of 43.20%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 38.16%. Given Rocket Pharmaceuticals’ rivals stronger consensus rating and higher probable upside, analysts clearly believe Rocket Pharmaceuticals has less favorable growth aspects than its rivals.

Earnings & Valuation

This table compares Rocket Pharmaceuticals and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Rocket Pharmaceuticals N/A -$29.49 million -3.07
Rocket Pharmaceuticals Competitors $267.94 million -$30.77 million -36.35

Rocket Pharmaceuticals’ rivals have higher revenue, but lower earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.


This table compares Rocket Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Rocket Pharmaceuticals N/A -53.72% -27.09%
Rocket Pharmaceuticals Competitors -6,275.64% -165.78% -36.81%

Risk & Volatility

Rocket Pharmaceuticals has a beta of 4.17, indicating that its share price is 317% more volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals’ rivals have a beta of 1.84, indicating that their average share price is 84% more volatile than the S&P 500.

Insider & Institutional Ownership

52.7% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 5.3% of Rocket Pharmaceuticals shares are held by company insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.


Rocket Pharmaceuticals rivals beat Rocket Pharmaceuticals on 7 of the 13 factors compared.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc., formerly Inotek Pharmaceuticals Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye’s trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases.

Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply